SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2005 / Cilt: 15 - Sayı: 3

The role of epidermal growth factor receptor inhibitors in the non-small cell lung cancer treatment

Küçük hücreli dışı akciğer kanserlerinde epidermal büyüme faktor reseptor (EGFR) inhibitörlerinin yeri

Özden ALTUNDAĞ
Kadri ALTUNDAĞ
Pages
165–174
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review we summarize recent developments in epidermal growth factor receptor inhibitors for non-small cell lung cancer treatment in the view of current pertinent literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recently significant progress has been achieved in the targeted treatment of lung cancer.
📊
Key Findings & Data:Recently significant progress has been achieved in the targeted treatment of lung cancer.
💡
Conclusion & Impact:In this review we summarize recent developments in epidermal growth factor receptor inhibitors for non-small cell lung cancer treatment in the view of current pertinent literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antineoplastik ajanlar · Karsinom · küçük hücreli dışı akciğer

Abstract

Recently significant progress has been achieved in the targeted treatment of lung cancer. In this review we summarize recent developments in epidermal growth factor receptor inhibitors for non-small cell lung cancer treatment in the view of current pertinent literature.

Özet

Son zamanlarda akciğer kanserinin hedefe yönelik tedavisinde önemli gelişmeler kaydedilmiştir. Bu derlemede küçük-hücreli dışı akciğer kanser tedavisinde kullanılan epidermal büyüme faktör reseptör inhibitorleriyle ilgili son gelişmeler konuyla ilişkili güncel makaleler ışığında özetlenmiştir.

🔖

Cite This Article

ALTUNDAĞ, Ö., ALTUNDAĞ, K. (2005). The role of epidermal growth factor receptor inhibitors in the non-small cell lung cancer treatment. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 15 - Sayı: 3, 165–174. https://ajindex.com/articles/323123

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Chemoradiotherapy in non-small cell lung cancer- a metaanalysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Cooperative Group. BMJ 311: 899-909, 1995
  2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866- 1872, 1993
  3. Fossella F, DeVore R, Kerr R, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000
  4. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004
  5. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Ann Rev Med 55: 433-457, 2004
  6. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10: 4227–4232, 2004 7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995
  7. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787- 2799, 2003
  8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004 10. Rubio ED, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5- fluorouracil (5-FU)/folinic acid (FA) (FOLFOX- 4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)- expressing metastatic colorectal cancer: An international phase II study [Abstract 3535]. Proc Am Soc Clin Oncol 22: 253s, 2004
  9. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab [Abstract 5507]. Proc Am Soc Clin Oncol 22: 489s, 2004
  10. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum- refractory recurrent/metast